BARICITINIB AMELIORATES BLEOMYCIN-INDUCED PULMONARY AND SKIN FIBROSIS VIA JAK 1/2 INHIBITON

Gulle, S.Celik, A.Lebe, B.Ulukus, C.Baris, M.Harmanci, D.Birlik, M.2024-08-312024-08-3120230003-49671468-2060https://doi.org/10.1136/annrheumdis-2023-eular.5329https://hdl.handle.net/11454/104928European Congress of Rheumatology (EULAR) -- MAY 31-JUN 03, 2023 -- Milan, ITALY[Abstarct Not Available]en10.1136/annrheumdis-2023-eular.5329info:eu-repo/semantics/openAccessLungsAnimal ModelsSystemic SclerosisBARICITINIB AMELIORATES BLEOMYCIN-INDUCED PULMONARY AND SKIN FIBROSIS VIA JAK 1/2 INHIBITONConference Object82588589WOS:001107398702025Q1